Australia-based medical device company Oventus Medical will unveil its O2Vent flagship product in the US later this month to treat snoring and sleep apnoea.

Cleared by the US Food and Drug Administration (FDA) 510k and enlisted under Australian Register of Therapeutic Goods (ARTG), the O2Vent is a 3D-printed titanium mandibular (jaw) advancement device that can fit in accordance to the patient’s size of the mouth.

It features a separate airway, which directs air to the back of the mouth avoiding the obstructions created by nose, back of the mouth and tongue, facilitating an improved airflow in the patients suffering from snoring and related sleep disorders.

A recent clinical trial conducted on the O2Vent in Australia has resulted to an elimination of snoring in 82% of patients and significantly reduced in all patients involved in the trial.

People with nasal obstructions who had to mainly breathe through their mouths, including when they were asleep, have also exhibited positive results.

"The trial also demonstrated that the device improves oxygen levels in most patients."

O2Vent developer and Oventus founder and clinical director Dr Chris Hart said: "The recent clinical trial data strongly showed that the O2Vent significantly reduced snoring and sleep apnoea in most patients studied, even in those who historically did not benefit from other treatments due to chronic nasal obstruction.

"The trial also demonstrated that the device improves oxygen levels in most patients.

"A greater number of patients who snore or who suffer from mild to moderate sleep apnoea but who are continuous positive airway pressure (CPAP) intolerant, now have an alternative treatment option available."

Image: An illustrative depiction of airway blockage leading to obstructive sleep apnoea. Photo: courtesy of Drcamachoent via Wikipedia.